Treatment of Patients With Type 2 Diabetes With an Interleukin-1 Antagonist
Status:
Completed
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
Aim: To investigate the therapeutic potential of IL-1Ra in type 2 diabetes.
Rationale: Since the major defect leading to a decrease in b-cell mass in type 2 diabetes is
increased apoptosis, therapeutic approaches designed to arrest apoptosis could be a
significant new development in its management. This approach might actually reverse the
disease to a degree rather than just palliate glycemia. Based on current thinking, treatment
with IL-1Ra appears as a promising approach. The prospected effect is blocking of the
IL-1b-mediated glucotoxicity and thereby to prevent the decline in b-cell mass, together with
a rapid restoration of b-cell function. FDA approval for IL-1Ra in the treatment of
rheumatoid arthritis occurred based on a favourable tolerability profile.
Phase:
Phase 2
Details
Lead Sponsor:
University of Zurich
Collaborators:
Steno Diabetes Center Steno Diabetes Center Copenhagen